Avalon globocare announces new study featuring ai-enhanced protein design technology targeting glucose transporter against cancer

Freehold, n.j., june 30, 2022 (globe newswire) -- avalon globocare corp. (nasdaq: avco), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (ai) enhanced protein design “qty code” technology. the method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer.
AVCO Ratings Summary
AVCO Quant Ranking